Article (Published version) (221 Kb) - 
Limited access to UNIGEOther version: http://rms.medhyg.ch/numero-175-page-2203.htm
Highlights
More informations
Scientific Article
unige:33832 
 |
Place des bêta-agonistes de longue durée dans le traitement de l'asthme bronchique |
|
| Authors | ||
| Published in | Revue médicale suisse. 2008, vol. 4, no. 175, p. 2203-4,2206-7 | |
| Abstract | Long acting beta2-agonists (LABA) are one of the most widely prescribed anti-asthmatic therapies. Nevertheless, their chronic utilization has been associated in large clinical studies with severe asthma exacerbations and asthma-related deaths raising concern about their safety. Awaiting further evidence to definitely identify susceptible subgroups, LABA should be used with caution. Inhaled corticosteroids (ICS) is the preferred asthma controller option and LABA should be used only in association with ICS in patients insufficiently controlled under ICS therapy. | |
| Keywords | Adrenal Cortex Hormones/therapeutic use — Adrenergic beta-Agonists/therapeutic use — Asthma/drug therapy — Clinical Trials as Topic — Humans | |
| Identifiers | PMID: 19024574 | |
| Full text |
Article (Published version) (221 Kb) - Limited access to UNIGE Other version: http://rms.medhyg.ch/numero-175-page-2203.htm |
|
| Structures | ||
| Citation (ISO format) | MARTI, Christophe Alberic, JANSSENS, Jean-Paul, RUTSCHMANN, Olivier Thierry. Place des bêta-agonistes de longue durée dans le traitement de l'asthme bronchique. In: Revue médicale suisse, 2008, vol. 4, n° 175, p. 2203-4,2206-7. https://archive-ouverte.unige.ch/unige:33832 |
188 hits 
0 download 
Contact an author
Update